35387-92-9

Basic information

• Product Name: METHYL-4-IODO-3-METHOXY BENZOATE
• Synonyms: METHYL-4-IODO-3-METHOXY BENZOATE;4-iodo-3-methoxyBenzoic acid methyl ester
• CAS NO: 35387-92-9
• Molecular Formula: C₉H₉IO₃
• Molecular Weight: 292.07
• Mol File: 35387-92-9.mol
• Article Data: 31

Chemical Properties

• Boiling Point: 324.3°Cat760mmHg
• Flash Point: 149.9°C
• Appearance: /
• Density: 1.684g/cm³
• Vapor Pressure: 0.000247mmHg at 25°C
• Refractive Index: 1.578
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: METHYL-4-IODO-3-METHOXY BENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL-4-IODO-3-METHOXY BENZOATE(35387-92-9)
• EPA Substance Registry System: METHYL-4-IODO-3-METHOXY BENZOATE(35387-92-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 35387-92-9(Hazardous Substances Data)

Usage

Description

METHYL-4-IODO-3-METHOXY BENZOATE is an organic compound that serves as a key reactant in the synthesis of isoquinolinediones, which are known to be inhibitors of cyclin-dependent kinase 4. METHYL-4-IODO-3-METHOXY BENZOATE plays a crucial role in the development of pharmaceuticals targeting specific cellular processes.
Used in Pharmaceutical Industry:
METHYL-4-IODO-3-METHOXY BENZOATE is used as a reactant for the preparation of isoquinolinediones, which are inhibitors of cyclin-dependent kinase 4. These inhibitors are valuable in the development of drugs that can regulate cell cycle progression and have potential applications in the treatment of various diseases, including cancer.

InChI:InChI=1/C9H9IO3/c1-12-8-5-6(9(11)13-2)3-4-7(8)10/h3-5H,1-2H3

Upstream product

• 186581-53-3 diazomethane 
• 58123-77-6 3-hydroxy-4-iodobenzoic acid 
• 41608-64-4 methyl 3-methoxy-4-aminobenzoate 
• 282087-44-9 4-iodo-3-(methyloxy)benzoic acid 
• 157942-12-6 methyl 3-hydroxy-4-iodobenzoate 
• 74-88-4 methyl iodide 
• 77-78-1 dimethyl sulfate 
• 2374-03-0 4-aminosalicylic acid 
• 63435-16-5 3-hydroxy-4-aminobenzoic acid methyl ester 
• 38512-82-2 3-methoxy-4-nitrotoluene 
• 5081-36-7 3-methoxy-4-nitrobenzoic acid 
• 5081-37-8 methyl 3-methoxy-4-nitrobenzoate 
• 39896-47-4 4-(3'-Methoxyphenyl)-DL-isovalin 
• 39896-53-2 4-(3'-Methoxy-4'-iodphenyl)-DL-isovalin 

Downstream Products

• 511295-16-2 5'-[2-(5-chloro-4'-hydroxymethyl-4,2'-dimethoxy-biphenyl-2-yl)-ethyl]-6,2'-dimethoxy-biphenyl-3-carbaldehyde 
• 511295-18-4 5-chloro-5'-[2-(5-chloro-4'-hydroxymethyl-4,2'-dimethoxy-biphenyl-2-yl)-ethyl]-6,2'-dimethoxy-biphenyl-3-carbaldehyde 
• 511295-13-9 5'-chloro-2'-[2-(5'-[1,3]dioxan-2-yl-6,2'-dimethoxy-biphenyl-3-yl)-ethyl]-2,4'-dimethoxy-biphenyl-4-carboxylic acid methyl ester 
• 511295-15-1 5'-chloro-2'-[2-(3'-chloro-5'-[1,3]dioxan-2-yl-6,2'-dimethoxy-biphenyl-3-yl)-ethyl]-2,4'-dimethoxy-biphenyl-4-carboxylic acid methyl ester 
• 208399-31-9 N,N',N''-(nitrilotri-2,1-ethanediyl)tris(2,2'-dihydroxy-4-biphenylcarboxamide) 
• 208399-30-8 N,N',N''-(nitrilotri-2,1-ethanediyl)tris(2,2'-dimethoxy-4-biphenylcarboxamide) 
• 282087-44-9 4-iodo-3-(methyloxy)benzoic acid 
• 175152-72-4 methyl 3-methoxy-4-phenylbenzoate 
• 1173176-92-5 (R)-1-(4-benzoyl-2-methylpiperazin-1-yl)-2-(4-iodo-3-methoxyphenyl)ethane-1,2-dione 
• 1269834-30-1 C₁₂H₁₂N₂O₃ 
• 1269834-29-8 methyl 4-(1H-imidazol-1-yl)-3-methoxybenzoate 
• 1269834-28-7 C₁₇H₁₅NO₃ 

Relevant articles and documents

C3-triiodocyclotriveratrylene as a key intermediate to fluorescent probes: Application to selective choline recognition

A new strategy to obtain fluorescent cyclotriveratrylene (CTV) probes is proposed. The key intermediate, a triiodo CTV, is prepared in 3 steps with 47% overall yield. The whole synthesis requires only one purification step. The potential of this triiodo C

Novel quinazoline-containing compound, and intermediate and application thereof

The present invention discloses a quinazoline-containing compound having the formula (IA), (IB) or (IC), or a pharmaceutically acceptable salt or a prodrug molecule thereof. The compound is suitable for use as an Aurora kinase inhibitor and is thus suitable for the treatment of Aurora-mediated diseases characterized by excessive or abnormal cell proliferation, for example, cancer.

Total synthesis of polymorphatin A, a macrocyclic bisbibenzyl with boat configured arenes

Polymorphatin A was reported as a constituent of Marchantia polymorpha in 2007 following much speculation as to its likely existence as a natural product. Interest was rekindled when a claimed total synthesis revealed inconsistencies in spectral data betw

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.